Universidad Peruana Cayetano Heredia

Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis

Mostrar el registro sencillo del ítem

dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Lescano Guevara, Andres Guillermo
dc.contributor.author Lanchote, V.L.
dc.contributor.author Pretell, E.J.
dc.contributor.author Gonzales, I.
dc.contributor.author Bustos Palomino, Javier Arturo
dc.contributor.author Takayanagui, O.M.
dc.contributor.author Bonato, P.S.
dc.contributor.author Horton, J.
dc.contributor.author Saavedra Pastor, Herbert
dc.contributor.author Gonzalez Zariquiey, Armando Emiliano
dc.contributor.author Gilman, Robert Hugh
dc.date.accessioned 2022-01-18T19:26:52Z
dc.date.available 2022-01-18T19:26:52Z
dc.date.issued 2011
dc.identifier.uri https://hdl.handle.net/20.500.12866/10969
dc.description.abstract Neurocysticercosis is the most common cause of acquired epilepsy in the world. Antiparasitic treatment of viable brain cysts is of clinical benefit, but current antiparasitic regimes provide incomplete parasiticidal efficacy. Combined use of two antiparasitic drugs may improve clearance of brain parasites. Albendazole (ABZ) has been used together with praziquantel (PZQ) before for geohelminths, echinococcosis and cysticercosis, but their combined use is not yet formally recommended and only scarce, discrepant data exist on their pharmacokinetics when given together. We assessed the pharmacokinetics of their combined use for the treatment of neurocysticercosis. METHODS A randomized, double-blind, placebo-controlled phase II evaluation of the pharmacokinetics of ABZ and PZQ in 32 patients with neurocysticercosis was carried out. Patients received their usual concomitant medications including an antiepileptic drug, dexamethasone, and ranitidine. Randomization was stratified by antiepileptic drug (phenytoin or carbamazepine). Subjects had sequential blood samples taken after the first dose of antiparasitic drugs and again after 9days of treatment, and were followed for 3months after dosing. RESULTS Twenty-one men and 11 women, aged 16 to 55 (mean age 28)years were included. Albendazole sulfoxide concentrations were increased in the combination group compared with the ABZ alone group, both in patients taking phenytoin and patients taking carbamazepine. PZQ concentrations were also increased by the end of therapy. There were no significant side effects in this study group. CONCLUSIONS Combined ABZ + PZQ is associated with increased albendazole sulfoxide plasma concentrations. These increased concentrations could independently contribute to increased cysticidal efficacy by themselves or in addition to a possible synergistic effect. en_US
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartofseries British Journal of Clinical Pharmacology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Peru en_US
dc.subject Young |Controlled Study en_US
dc.subject Drug Efficacy en_US
dc.subject Hematologic Disease en_US
dc.subject Ranitidine en_US
dc.subject Clinical |Randomized Controlled Trial en_US
dc.subject Albendazole en_US
dc.subject Drug Therapy Combination en_US
dc.subject Taenia Solium en_US
dc.subject Blood Sampling en_US
dc.subject Anthelmintics en_US
dc.subject Praziquantel en_US
dc.subject Double Blind Procedure en_US
dc.subject Drug Safety en_US
dc.subject Neurocysticercosis en_US
dc.subject Albendazole Sulfoxide en_US
dc.subject Praziquantel en_US
dc.subject Drug Potentiation en_US
dc.subject Carbamazepine en_US
dc.subject Dexamethasone en_US
dc.subject Gastrointestinal Symptom en_US
dc.subject Intracranial Hypertension en_US
dc.subject Phase 2 Clinical Trial en_US
dc.subject Phenytoin en_US
dc.title Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1111/j.1365-2125.2011.03945.x
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn 1365-2125


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas